SGLT2 Inhibitor Prescription Rates Lag Behind in HFrEF, with Stephen Greene, MD
June 13th 2023Stephen Greene, MD, discusses the results of a recent GWTG-HF registry analysis, which concluded just 1 in 5 hospitalized patients with HFrEF were discharged with an SGLT2 inhibitor prescription and less than 10% were receiving all 4 classes of guideline-directed medical therapy.
Disease Activity-Guided Dosing Safe, Effective for up to 10 Years in Rheumatoid Arthritis
June 6th 2023Noortje van Herwaarden, MD, PhD, discusses the results of a 10-year follow-up from the DRESS study and how it informs use of disease activity-guided dose optimization in treatment of rheumatoid arthritis.
SGLT2 Inhibitors Could Lower Risk of Recurrent Gout Flares in People with Diabetes
June 4th 2023A new-user, active comparator cohort study from EULAR 2023 suggests use of SGLT2 inhibitors could lower risk of recurrent gout flares in people with type 2 diabetes and gout compared to use of DPP-4 inhibitors.